Drug of Synthetic Peptides
Development of Technology for Production of Drugs and Diagnostics on the Base of Synthetic Peptides.
Tech Area / Field
- MED-DRG/Drug Discovery/Medicine
3 Approved without Funding
Institute of Highly Pure Biopreparations, Russia, St Petersburg
- Freie Universität Berlin, Germany, Berlin\nMinistère de la Défense/Service des Recherches / Division Biologie-Physiologie, France, Paris
Project summaryThe proposed project aims to develop therapeutic preparations based on synthetic peptide substances, which involves the development of the optimal technologies for production of the substances, the preclinical trials of peptide-preparations, the development of drug forms, the clinical trials, and the manufacturing of pilot batches of the preparations.
Within the project it is planned to develop two therapeutic preparations based on synthetic peptides. These are deglycineamide-vasopressin and the peptide preparation based on the regulatory protein fragment which was selected following biological screening, possesses the immunomodulatory activity and potentiates the efficacy of hepatitis В vaccine.
The proposed peptide substances, that is regulatory protein fragments possess the necessary biological effects without showing side effects specific for large native molecules. Moreover, synthesis of short peptides is economically more profitable as compared with genetically engineered synthesis of proteins, or their isolation from natural raw materials The use of selectively acting deglycineamide-vasopressin to prevent and correct hemorrhagic diatheses is undoubtedly more advisable as this preparation has no hormonal (antidiuretic and pressor) activities and does not require the joint use of aminocapronic acid like the case of vasopressin, owing to the absence of fibronolytic activity.
Besides, the advantages of using peptide preparations in pathologies of the blood coagulation system are also the decrease in risk of infecting patients with hepatitis viruses and HIV, and the decrease in necessary quantity of donor blood.
The characteristic property of the proposed project is the use of the adaptable process scheme, which permits to use the same equipment for production of peptides with different sequences in quantities necessary for clinical trials, and also to manufacture pilot batches of the preparations.
Besides, within the project it is planned to develop the high-sensitivity diagnostic for enzyme immunoassay of insulin, to produce pilot batches of the diagnostic, and to carry out its clinical tests.
The project provides opportunites to the Institute's 28 scientists and engineers who possess knowledge and skills in the field of development of protective means against biological weapons to focus their scientific-technical potential on research directed to achieve peaceful purposes only.
All the above-said factors testify to the advisability of executing the works of the. project which complies with the ISTC objectives, and undoubtedly requires the support.